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Abstract
Background: Neuropathic pain has been little studied in leprosy. We assessed the prevalence and clinical characteristics of
neuropathic pain and the validity of the Douleur Neuropathique 4 questionnaire as a screening tool for neuropathic pain in
patients with treated leprosy. The association of neuropathic pain with psychological morbidity was also evaluated.
Methodology/Principal Findings: Adult patients who had completed multi-drug therapy for leprosy were recruited from
several Bombay Leprosy Project clinics. Clinical neurological examination, assessment of leprosy affected skin and nerves
and pain evaluation were performed for all patients. Patients completed the Douleur Neuropathique 4 and the 12-item
General Health Questionnaire to identify neuropathic pain and psychological morbidity.
Conclusions/Significance: One hundred and one patients were recruited, and 22 (21.8%) had neuropathic pain. The main
sensory symptoms were numbness (86.4%), tingling (68.2%), hypoesthesia to touch (81.2%) and pinprick (72.7%).
Neuropathic pain was associated with nerve enlargement and tenderness, painful skin lesions and with psychological
morbidity. The Douleur Neuropathique 4 had a sensitivity of 100% and specificity of 92% in diagnosing neuropathic pain.
The Douleur Neuropathique 4 is a simple tool for the screening of neuropathic pain in leprosy patients. Psychological
morbidity was detected in 15% of the patients and 41% of the patients with neuropathic pain had psychological morbidity.
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Introduction
Leprosy
Leprosy is a chronic granulomatous disease caused by
Mycobacterium leprae that principally affects skin and peripheral
nerves.[1] Leprosy is still present throughout the tropics and sub-
tropics. Worldwide 249,007 new cases were registered in 2008
with India registering 134,184.[2] Leprosy affects peripheral
nerves causing enlargement, sensory loss and motor weakness,
and nerve fibres in the skin causing loss of sensation in affected
skin sites. The M.leprae infection is treated with multi-drug therapy
(MDT) and all patients receive either dual or triple drug therapy
for up to 12 months. MDT is highly effective with a relapse rate of
1%. New nerve damage is treated with steroid therapy, but only
about 50% of patients will have improvement in nerve function
after a course of steroid treatment.[3] Leprosy is also complicated
by further episodes of inflammation affecting skin and nerves.
These may be Type 1 reactions associated with delayed type
hypersensitivity which cause inflammation affecting skin and
nerves. Type 2 or erythema nodosum leprosum (ENL) reactions
are associated with immune complex deposition and systemic
inflammation is seen with involvement of skin, nerves, eyes, bones
and testes. Inflammation of nerves is prominent in leprosy
pathology.[4]
Neuropathic pain
Neuropathic pain is defined as ‘‘pain arising as a direct
consequence of a lesion or disease affecting the nervous system’’.[5]
This may be due to nerve damage at a peripheral or central level.
Neuropathic pain typically persists after the primary cause has
resolved. Neuropathic pain is characterised by positive and negative
symptoms including pain, hypoesthesia to touch, tingling, electric
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shocks and pins and needles. The diagnosis of neuropathic pain rests
on clinical judgement, a relevant clinical history and clinical
neurological examination.[6] The patients should complain of pain
that is not generated by a stimulus and it must be in one or more
regions related to affected nerves (anatomic plausibility). A diagnosis
of probable neuropathic pain can be made if 1) clinical examination
shows positive or negative sensory signs confined to innervation
territory of the lesioned nervous structure or if 2) diagnostic tests can
confirm lesion or disease explaining the neuropathic pain. If both of
these criteria are met, the diagnosis of definite neuropathic pain can
be made.[7]
Several diagnostic questionnaires have been developed to alert
the clinician about the possibility of neuropathic pain, for example
the Douleur Neuropathique 4 (DN4). The DN4 consists of seven
items related to sensory descriptors and three related to signs
which require a simple clinical examination.[8] It examines the
positive and negative sensory symptoms of neuropathic pain, such
as evoked pain and hypoesthesia to touch. The DN4 has a
sensitivity of 83% and specificity of 90%.[8]
Neuropathic pain in leprosy
Little is known about neuropathic pain in leprosy patients.
26.4% of 358 newly presenting leprosy patients from a referral
centre in Brazil had neuropathic pain.[9] 29% of 96 Ethiopian
patients who had been treated for leprosy more than 10 years
earlier had neuropathic pain, which was ‘‘severe’’ in 43%.[10]
The clinical presentation of neuropathic pain in leprosy patients
can be continuous or intermittent and occur at a single or multiple
locations. Studies in India and Brazil found most patients with
neuropathic pain had a ‘‘glove and stocking’’ symptom distribu-
tion, characteristic of polyneuropathy [9,11], and in the Indian
study neuropathic pain was associated with nerve tenderness.[11]
Psychological morbidity in leprosy and neuropathic pain
Several studies have shown increased prevalence of psycholog-
ical morbidity in patients with leprosy. In some series, up to 65%
of patients have psychological morbidity, depression being the
most common.[12,13,14] Chronic neuropathic pain has also been
associated with psychological and quality of life comorbidities,
including circadian rhythm disturbance, anxiety and depres-
sion.[15] So leprosy and neuropathic pain may have separate and
perhaps synergistic contributions to psychological morbidity.
Non-psychotic mental disorders are defined in ICD-9 as
‘‘disorders in which the symptoms are distressing to the individual
and recognized by him or her as being unacceptable’’.[16] The
General Health Questionnaire-12 (GHQ-12) is used to detect the
presence of non-psychotic psychological morbidity. It is a self-
reporting questionnaire intended for use in a primary health care
setting.[17] It consists of 12 questions, asking patients about their
general level of happiness, experience of depressive and anxiety
symptoms, and sleep disturbance over the last four weeks.[15]
This cross-sectional study was designed to assess the prevalence
and characteristics of neuropathic pain in leprosy patients who
have completed MDT. From previous studies [11,18], we
expected a prevalence of approximately 15%, because the patients
were recruited at a referral centre. This would be higher than in
the general population [19,20], and lower than in patients with
diseases in which neuropathic pain is the main feature, such as
diabetes or stroke.[21,22]. Neuropathic pain was assesed using
clincial examination. We also assesd pain using the DN4
questionnaire. Psychological morbidity was assesed using the
GHQ-12. With this study design we were able to asses the
prevalence of neuropathic pain. We also tested the utility of the
DN4 as a screeening tool for neuropathic pain in this group. We
also predicted that we would find increased psychological
morbidity in the patients with neuropathic pain.
Methods
Patients
Between July and August 2008, we enrolled 101 patients (73
male [72.3%]; 28 female [27.7%]) from Bombay Leprosy Project
clinics in the state of Maharashtra, India. Every patient (estimate
n= 150) over the age of 16 who attended the clinics during the
study period and had taken a full course of MDT was invited to
participate. We did not collect reasons for non participation in the
study as we should have done. This sample size was used because
we estimated that we would detect about 20 patients with
neuropathic pain.
Diagnosis of leprosy
Leprosy was diagnosed when a patient had one of the following:
skin lesions typical for leprosy; and/or thickened peripheral
nerves; and/or acid fast bacilli on slit skin smears.[23] Patients
with leprosy were then classified using the 1998 WHO
classification in which patients are classified as paucibacillary
(PB) if they have up to five skin lesions and as multibacillary (MB)
if they have five or more skin lesions.[23] The Ridley-Jopling
classification was made on the basis of the clinical features and
bacterial index.[24]
Case definition for neuropathic pain. Patients were
defined as having neuropathic pain if distribution of pain was
neuroanatomically plausible, confirmatory tests of neurological
examination demonstrated positive or negative sensory signs
confined to the innervation territory of the affected peripheral
nerves, and pain was causally associated with having had leprosy.[7]
Procedures
All patients were given a blank body chart (Figure 1) and asked to
draw in any areas of pain. The clinician used the same chart to draw
patches or skin lesions. A clinical history was then taken. Data was
Author Summary
Neuropathic pain has only recently been recognised as a
complication of leprosy. We assessed 101 treated leprosy
patients in Mumbai and found that 22 of them had
neuropathic pain. The pain occurred as numbness 86%,
tingling 68%, and decreased sensation to light touch 81%.
This pain was significantly associated with nerve enlarge-
ment and tenderness, which suggests that ongoing
inflammation may be important in causation. A question-
naire-based screening tool (Douleur Neuropathique 4) for
detecting neuropathic pain has been developed and
validated in other patients groups. We are the first group
to have used the DN4 as a screening tool in leprosy
patients and found that it worked well, detecting 78% of
patients with no inappropriate diagnoses. There is also an
increasing recognition that leprosy is associated with
psychological morbidity. Neuropathic pain is also associ-
ated with psychological morbidity. We also assessed
psychological morbidity using the 12-item General Health
Questionnaire and found that neuropathic pain and
psychological morbidity are associated with leprosy
patients. Leprosy patients with neuropathic pain thus
have a double hit for psychological morbidity. Clinicians
looking after leprosy patients should warn their patients
about neuropathic pain and assess their patients for
psychological morbidity.
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collected on past medical history, diagnosis of leprosy, leprosy
antibiotic treatment, leprosy reactions (Type 1, ENL, Neuritis), past
and current treatments for leprosy reactions, including corticoste-
roids, thalidomide, azathioprine and chloroquine. This was
followed by a clinical evaluation and the patients completed the
DN4 and GHQ-12 questionnaires. The DN4 was translated into
Hindi and Marathi, and the GHQ-12 was translated to Hindi and
simultaneously translated to Marathi when needed.
Nerve evaluation
Nerve enlargement and tenderness was clinically evaluated by
palpation of the main peripheral nerves (great auricular, ulnar,
Figure 1. Body chart.
doi:10.1371/journal.pntd.0000981.g001
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median, lateral popliteal and posterior tibial), and defined as
present or absent. Motor function was tested in the following
nerves by assessing the muscle they supply: facial nerve (orbicularis
oculi) ulnar nerve (abductor digiti minimi), median nerve
(opponens pollicis) and common peroneal nerve (extensor hallucis
longus). Sensory testing was done using a series of Semmes-
Weinstein monofilaments (MF) (0.05 gm / 0.2 gm / 2 gm / 4 gm
/ 10 gm / 300 gm) to assess punctate static light touch perception
in skin areas supplied by the ulnar, median and posterior tibial
nerves.[25] Perception was assessed using a Yes/No response.
Sensory impairment was defined as present when the MF
threshold increased by three or more levels (filaments) on any
site, or two levels on one site and at least one level on another site,
or one level on three or more sites for one nerve [26], with a lower
limit of 0.2 gm MF perception on the hands, face and leprosy skin
lesions, and for 2 gm on the foot.
Disability assessment
The WHO disability criteria, which has three levels, 0, 1 and 2,
was used to document disability. Zero is scored when no disability
is present, 1 when loss of sensation in hand or foot is present, and 2
when there is visible damage or disability including deformity,
lagophthalmos or hand or foot ulcer.[25]
Neuropathic pain assessment and questionnaires
Both DN4 and GHQ-12 questionnaires were completed by the
patient, with the clinician asking the questions since many patients
were not functionally literate. When completing the DN4
questionnaire, if the patient had any of the symptoms, the area
in which s/he had it was recorded beside each symptom. In these
cases a clinical assessment of the area was undertaken, evaluating
‘hypoesthesia to touch’ by applying light touch with finger on the
painful area and a non-painful area simultaneously, and
‘hypoesthesia to pinprick’ using the 300 g MF. Dynamic
mechanical allodynia was evaluated using a brush on the painful
area and patients responded Yes/No to the evoking of pain.
For the GHQ-12, the patients were asked how they had felt
during the past four weeks. If they had any symptoms, they were
asked what cause they attributed to them. Interpretation of the
answers is based on a four point response scale scored using a
bimodal method (symptom present: ‘not at all’ = 0, ‘same as
usual’ = 0, ‘more than usual’ = 1 and ‘much more than usual’ = 1).
A score of four or more indicates the presence of a disorder, without
diagnosing the exact pathology.[17]
Ethical approval
Ethical approval was received from the London School of
Hygiene and Tropical Medicine Ethics Committee prior to
commencing the study. Ethical approval in India was received
from the Bombay Leprosy Project Managing Committee.
Informed consent
On recruitment, patients were given an explanation of the
study, which was translated to Hindi or Marathi when needed
before being invited to sign the consent form which was also in
Hindi and Marathi. No patient was paid to participate in the
study.
Statistical analysis
A database was created using a Microsoft Excel spreadsheet,
and analysed using Stata 10.1. A x2 test was then used comparing
all the variables to the outcome variables neuropathic pain,
psychological morbidity, and presence of disability. For those
variables with a significant p value a Mantel-Haenszel test was
performed (Table 1). Missing data related mainly to aspects of the
patients medical history.
Results
One hundred and one patients were recruited (73 male
[72.3%]; 28 female [27.7%]), age range 17 to 89 years (mean
39.3, sd615.89), of whom 22 (21.8%) had neuropathic pain.
Ninety four patients (93%) had MB leprosy, and 7 (7%) had PB
leprosy. Most patients (73%) had been diagnosed and treated for
leprosy between 2001 and 2007; 20 between 1991 and 2000.
During the period of recruitment about 150 patients were
reviewed from urban and rural areas in the Bombay Leprosy
Project clinics.
Clinical findings (Table 1)
Sixty nine patients (68.3%) had ongoing skin involvement with
patches, nodules, ulcers or infiltration. Twenty four (23.8%) had
painful skin lesions, of whom 9 (37.5%) had neuropathic pain.
Forty six patients (45.5%) had nerve enlargement and 19 (18.8%)
had nerve tenderness. Nerve enlargement was present in one nerve
only in 14 patients (30.4%) and in multiple nerves for 32 (69.6%).
Nerve enlargement was found most often in the ulnar nerve
(65.22%), then the lateral popliteal (43.5%), posterior tibial
(39.1%) and greater auricular (37.0%) nerves. Nerve tenderness
was most commonly elicited in the ulnar nerve (68.4%), followed
by the posterior tibial (57.9%), lateral popliteal (31.6%) and great
auricular (15.8%) nerves.
Ulnar nerve motor impairment was detected in 35 patients
(34.7%). Combining motor and sensory testing, 65 patients had
ulnar nerve impairment (64.4%) and 42 (41.6%) median nerve
impairment. Seventy patients (69.3%) had plantar sensory
impairment. Sensory testing detected impairment in the areas
supplied by the lateral and medial plantar (69.3%), ulnar (45.5%),
median (38.6%) and trigeminal (6.9%) nerves.
Neuropathic pain (Table 2)
Twenty two patients had neuropathic pain (21.8%) by the
clinical definition, and Table 2 gives the features of the pain.
Neuropathic pain occurred in areas supplied by ulnar (6), lateral
popliteal (6), plantar medial and lateral (4), posterior tibial (2), sural
(1), trigeminal (1), tibial anterior (1) and median (1) nerves
respectively. Eleven patients had pain in one limb only and 11 had
pain affecting both limbs, either arms or legs. Twenty one patients
with neuropathic pain had sensory impairment (95.5%) and 11
(50.0%) had motor impairment. Nine (40.9%) had painful leprosy
skin lesions in addition to the areas of neuropathic pain associated
with nerve trunks or cutaneous nerves.
Patients described sensory symptoms as numbness (19), tingling
(15), burning sensation (13), electric shocks (11), pins and needles
(10), painful cold (6) and three had itching and these symptoms
overlapped in individual patients. Eighteen patients had hypoes-
thesia to touch in the painful area, 16 had hypoesthesia to
pinprick, and one had allodynia.
Twenty eight (27.7%) patients scored 4 or more on the DN4
questionnaire whilst 22 had neuropathic pain by the clinical
definition. None of the patients clinically diagnosed with
neuropathic pain scored less than 4 on the DN4. These six
patients experienced some of the symptoms listed in the
questionnaire occasionally in a certain area, but without pain or
discomfort. One patient had pain with no anatomical plausibility.
In this group the DN4 used for screening for neuropathic pain had
a sensitivity of 78.6% and a specificity of 100%.
Neuropathic Pain in Leprosy Patients, Mumbai
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Psychological morbidity
Fifteen (14.9%) patients had psychological morbidity, mainly
anxiety, mild or incipient depression, which they associated with
having leprosy. Forty one percent of the patients with neuropathic
pain had psychological morbidity. Some patients who scored less
than 4 on the GHQ-12 explained that although they had some
symptoms, such as lack of sleep or increased strain, they felt that
these were not associated with their leprosy.
Disability
Forty four patients (43.6%) had disability, eight had grade 1
(7.9%), and 36 grade 2 (35.6%). Of the 22 patients with
neuropathic pain, 11 (50%) had disability grade 0, five had grade
1 (22.7%) and six grade 2 (27.3%).
Neuropathic pain is significantly associated with psychological
morbidity (p= 0.0001), nerve enlargement (p= 0.016), nerve
tenderness (p= 0.0003), trigeminal nerve impairment (p= 0.0194),
and painful skin patches (p= 0.0335) (Table 3). No significant
association was found between neuropathic pain and sex, age, type
of leprosy (WHO or Ridley-Jopling), presence or type of reaction,
type of treatment for leprosy, other treatments (prednisolone,
thalidomide, chloroquine and azathioprine) or disability. Psycho-
logical morbidity was also significantly associated with nerve
tenderness (p= 0.024, OR=3.74, 95% CI 1.09–12.77).
Discussion
The study found a high prevalence of neuropathic pain (21.8%)
among patients with treated leprosy at a referral centre in India.
Neuropathic pain was associated with nerve enlargement and
tenderness, and painful skin patches. Psychological morbidity was
also significantly associated with neuropathic pain. In all patients,
the diagnosis of definite neuropathic pain could be made because
they had an established diagnosis of leprosy, and also positive and
negative sensory signs on clinical neurologic examination corre-
lating with the peripheral nerves that are affected in leprosy.[7]
The prevalence of neuropathic pain in treated leprosy patients
was higher than expected from clinical practice, but similar to that
found in patients with diabetic neuropathy in India (26.1%).[27]
Comparing with other infectious disease aetiologies, post herpetic
neuralgia has been reported in 13.4% of general practice patients
in the UK [28] whilst HIV sensory neuropathy affects 42% of
patients in Australia.[29] Patients and health care workers
probably pay more attention to the symptoms of leprosy itself
than to the diagnosis of pain, and appropriate tools and training
for diagnosis are not always available.
Our study design, a cross sectional prevalence study, means that
the patients in this study are typical of patients who attend leprosy
clinics with post-treatment complications. Thus we had a bias
Table 1. Patient characteristics according to presence or absence of neuropathic pain.
Patients with neuropathic
pain (*) N=22
Patients without neuropathic
pain (**) N=79 TOTAL (***) N=101
Sex Male 14 (63.6%) 59 (74.7%) 73 (72.3%)
Female 8 (36.4%) 20 (25.3%) 28 (27.7%)
Mean age 39.91 years 39.19 years 39.34 years
WHO classification MB 20 (90.9%) 74 (93.7%) 94 (93.1%)
PB 2 (9.2%) 5 (6.3%) 7 (6.9%)
Leprosy reaction present 15 (68.2%) 51 (64.6%) 66 (65.4%)
Type of reaction Type 1 reaction 7 (31.8%) 17 (21.6%) 24 (23.8%)
ENL 7 (31.8%) 28 (35.4%) 35 (34.7%)
Neuritis 1 (4.5%) 2 (2.5%) 3 (3.0%)
Silent neuritis 0 4 (5.1%) 4 (4.0%)
No reaction 7 (31.8%) 28 (35.4%) 34 (33.7%)
Other treatments Prednisolone 18 (81.8%) 48 (60.8%) 66 (65.4%)
Thalidomide 3 (13.6%) 23 (29.1%) 26 (25.7%)
Chloroquine 3 (13.6%) 16 (20.3%) 19 (18.8%)
Azathioprine 1 (4.5%) 9 (11.4%) 10 (9.9%)
Presence of patches 16 (72.7%) 53 (67.1%) 69 (68.3%)
Painful patches 9 (40.9%) 15 (19.0%) 24 (23.8%)
Thickened nerves 15 (68.2%) 31 (39.2%) 46 (45.5%)
Tender nerves 10 (45.5%) 9 (11.4%) 19 (18.8%)
Sensory impairment 21 (95.5%) 60 (76.0%) 81 (80.2%)
Motor impairment 11 (50.0%) 35 (44.3%) 46 (45.5%)
DN4 score ,4 / 10 0 73 (92.4%) 73 (72.3%)
$4 / 10 22 (100.0%) 6 (7.6%) 28 (27.7%)
Psychological morbidity 9 (40.9%) 6 (7.6%) 15 (14.9%)
Disability (WHO score of 1 or 2) 11 (50.0%) 33 (41.8%) 44 (43.6%)
*% of total patients with neuropathic pain (22);
**% of total patients without neuropathic pain (79);
***% of total sample population (101).
doi:10.1371/journal.pntd.0000981.t001
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towards patients with MB leprosy which is not surprising because
patients with MB leprosy are at a higher risk of developing nerve
damage and reactions.[26] This also explains why 65% of patients
in this study had experienced a past or current reaction. Future
prospective studies could examine the effect of reactions on
neuropathic pain better and also the association with PB leprosy.
However, our findings still reflect the magnitude of the problem
amongst patients attending leprosy clinics and show the need for
‘‘care after cure’’ programmes and research in this field. In 2007, a
research workshop recommended studies on the epidemiology of
neuropathic pain in leprosy as a research priority.[30]
We found a significant association between neuropathic pain
and nerve enlargement. Nerve enlargement is one of the
diagnostic criteria for leprosy and is present in significant numbers
Table 2. Features of neuropathic pain in patients.
Limb
affected Patient
Age /
Gender
Distribution of
neuropathic pain
Distribution of
nociceptive pain Thickened nerves Tender nerves
DN4
score
Upper 78 28/M Ulnar nerves bilaterally None Right ulnar nerve, posterior
tibial nerves bilaterally
Ulnar and posterior tibial
nerves bilaterally
4
80 50/M Ulnar nerves bilaterally None Left great auricular nerve,
ulnar nerves bilaterally, right
common peroneal nerve
Left great auricular nerve,
ulnar nerves bilaterally, right
common peroneal nerve
5 (?)
84 75/M Right ulnar nerve None Ulnar nerves bilaterally, left
posterior tibial nerve
Ulnar nerves bilaterally, left
posterior tibial nerve
6
87 18/F Right ulnar nerve None None Right ulnar nerve 5
101 21/F Right thumb None Left ulnar nerve, posterior
tibial nerves bilaterally
None 4
Lower 1 49/M Right peroneal nerve
and right plantar nerve
None None None 5
17 50/M Sural and peroneal
nerves bilaterally
Elbows Right ulnar and great
auricular nerves
None 5
20 19/F Left peroneal nerve Left arm and hip None None 5
24 54/F Soles of both feet None None None 6
26 28/M Left peroneal nerve,
soles of both feet
Left ankle and knee None None 7
41 65/M Both calves, right sole,
left heel
None Common peroneal nerves
bilaterally
Common peroneal nerves
bilaterally
6
43 26/M Both soles None Ulnar and posterior tibial
nerves bilaterally, left
common peroneal nerve
Ulnar and posterior tibial
nerves bilaterally
6
50 43/F Right deep peroneal
nerve
Right toe Right posterior tibial nerve Ulnar nerves bilaterally, right
posterior tibial nerve
7
76 25/M 1st and 2nd toes of left
foot
None Great auricular, ulnar and
common peroneal nerves
bilaterally, right tibial
posterior nerve
None 4
Both 3 33/M Right ulnar nerve and
distal symmetric
polyneuropathy
None Right great auricular nerve None 6
29 52/M Right auricular nerve,
dorsum of right foot,
sole of left foot
None Right ulnar and posterior
tibial nerve
Right posterior tibial nerve 8
49 45/F Distal symmetric
polyneuropathy
None None None 5
56 43/M 1st and 2nd branches
of left trigeminal nerve,
left big toe
None Great auricular nerves
bilaterally
None 6
62 30/M Distal symmetric
polyneuropathy
None Right ulnar nerve Right ulnar nerve, left
posterior tibial nerve
4
66 43/F Distal symmetric
polyneuropathy
None Ulnar nerves bilaterally Right ulnar nerve, common
peroneal and posterior tibial
nerves bilaterally
5
94 28/M Ulnar nerves bilaterally,
both soles and right foot
None Ulnar and posterior tibial
nerves bilaterally, left
common peroneal nerve
None 4
96 46/F Peroneal nerves bilaterally,
right index finger
None None None 4
doi:10.1371/journal.pntd.0000981.t002
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of new patients. However, the persistence of nerve enlargement
after treatment suggests that there is ongoing disease in the
peripheral nerves of our patients with neuropathic pain. The
association with nerve tenderness is also important because this is
evidence of ongoing inflammation in the patients with neuropathic
pain. A previous study by Lund et al in 17 patients with
neuropathic pain attending a leprosy clinic in Hyderabad found
nerve tenderness in multiple nerves.[11] Nerve biopsies were taken
from nine patients and nearly all of them showed neural
inflammation and also fibrosis. The association with tender nerves
indicates that acute nerve damage may result in chronic injury.
This again highlights the importance of early diagnosis in leprosy
so that nerve inflammation can be reduced. Further research on
this could include nerve biopsies or nerve ultrasound, when
available, to detect changes in nerve structure due to inflammation
or fibrosis.[31,32] However, it is also possible that leprosy patients
who have reactions and associated acute nerve inflammation
might at that point be experiencing the single episode pathogenesis
that patients with post herpetic neuralgia experience. Further
studies will need to delineate the contributions of leprosy-
associated acute and chronic inflammation to leprosy neuropathic
pain.
The relationship of neuropathic pain with painful skin patches
will require further histopathological studies such as skin biopsy
evaluation of intra-epidermal nerve fibre assessment. The patients
in this study are probably typical of patients who attend leprosy
clinics with late complications. Sixty-six percent of patients had
ongoing or a history of leprosy reactions and their medication,
including steroids, thalidomide and other immunosuppressants,
reflects this. It is interesting that similar numbers of patients with
and without pain are taking steroids. It is interesting that we did
not find an association between use of thalidomide and
neuropathic pain, since painful neuropathy is a well recognised
adverse affect of thalidomide.[33] Thalidomide has not been
reported to produce neurological sequelae in leprosy patients
taking it for ENL although there have not been any well designed
prospective studies of this.[34] Those patients who are discharged
from the leprosy clinics as ‘‘cured’’ may not wish to access these
health facilities in the future.
The DN4 questionnaire performed well in this group and the
resource poor field setting with a sensitivity of 100% and a
specificity of 92% which compares well with other analyses.[8] In
Turkish patients the DN4 had a sensitivity of 95% and a specificity
of 96.6%.[35] None of the patients who were clinically diagnosed
as having neuropathic pain scored less than 4 on the DN4
questionnaire, although six patients with a score of 4 or more were
not diagnosed as having neuropathic pain. The DN4 was easy to
implement and understand both for the clinician and the patient,
both in English, and its translations to Hindi and Marathi. The
patients clearly described the symptoms listed in the questionnaire,
independent of their educational level.
Leprosy patients have a large burden of post-disease complica-
tions which are not easy to detect since the patient will not always
access leprosy clinics, and health workers at general health
facilities may not be able to diagnose and treat them. Neuropathic
pain is a chronic complication that could possibly be prevented if
nerve damage is detected at an early stage and appropriate
treatment with corticosteroids is started. Although steroid
treatment of even early nerve damage has a variable efficacy with
50–65% of patients responding with improved nerve function after
a course of steroid treatment.[36]
The association of neuropathic pain with psychological
morbidity increases the importance of neuropathic pain, not only
as a physical symptom, but as a possible cause of psychiatric co-
morbidity. A study on HIV associated neuropathy in South East
Asia found that 20% of patients had sensory neuropathy and 36%
evidence of depression.[37] Reverse causality cannot be fully
discarded, since psychiatric patients have been shown to have a
decreased threshold for pain.[22] This finding also highlights the
importance of including mental state and depression evaluations in
studies of neuropathic pain, especially if tricyclic antidepressants
were to be tested for efficacy in treating neuropathic pain.
No randomised controlled trials of analgesic treatment for
neuropathic pain in leprosy or even well designed exploratory
studies have been reported.[38] A study in Brazil set the guidelines
for treatment, using drugs which have been tried in patients
without leprosy.[39] Steroids are commonly used in leprosy to
alleviate the pain, due to their action on inflammation; they are
not, however, specific treatments for the neuropathic pain itself.
Different classes of drugs such as tricyclic antidepressants therefore
need to be tested.
The main weakness of the study was that the grading of the pain
intensity was not done. We also did not systematically exclude
potential other pathologies such as diabetes or post herpetic
neuralgia. This should be done in future studies. Furthermore, the
diagnosis of psychological morbidity was not based on clinical
psychiatric evaluation but on GHQ-12 scores only. For the
questionnaire, we used the Hindi translation, which often had to
be simultaneously translated to Marathi, and which has not yet
been validated, and this may therefore have altered the results.
Conclusions
The study demonstrates a high prevalence of neuropathic pain
in patients who have completed treatment for leprosy and are
generally not accounted for in leprosy statistics. The main
symptom was numbness (86.4%) followed by tingling (68.2%),
which differs from the findings from other studies.
The DN4 is a useful and simple tool for the screening of
neuropathic pain, which makes it appropriate for leprosy field
work. Its high specificity in the study is important in its further
application outside research environment, considering the chronic
implications of neuropathic pain.
The relationship of neuropathic pain with psychological
morbidity found in this study further increases the magnitude of
the problem. It will be important to continue research in this field
Table 3. Analysis of association of neuropathic pain with key
leprosy clinical features.
Variable P OR 95% CI
Sensory impairment 0.0434 6.65 0.79–55.71
Mild 0.4953 1.58 0.42–6.00
Moderate 0.4294 1.90 0.38–9.59
Severe 0.9657 1.03 0.24–4.45
Motor impairment 0.6368 1.26 0.48–3.26
Psychological morbidity 0.0001 8.42 2.30–30.79
Thickened nerves 0.0165 3.32 1.17–9.39
Tender nerves 0.0003 6.48 2.01–20.95
Facial sensory
impairment
0.0194 5.62 1.02–28.90
Presence of disability 0.4934 1.39 0.70–6.80
Analyses done with The Mantel-Haensel test.
doi:10.1371/journal.pntd.0000981.t003
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in order to attend the needs of these patients in terms of
prevention, diagnosis and treatment.
Supporting Information
Checklist S1 STROBE checklist
10.1371/journal.pntd.0000981.s001 (0.09 MB DOC)
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